ACTUATE THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • March 4th, 2024 • Actuate Therapeutics, Inc. • Services-commercial physical & biological research • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of February 17, 2024 between ACTUATE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and Paul Lytle (“Indemnitee”).
EXCLUSIVE LICENSE AGREEMENT WITH EQUITYExclusive License Agreement • March 4th, 2024 • Actuate Therapeutics, Inc. • Services-commercial physical & biological research • Illinois
License Agreement (“Agreement”), effective as of April 6, 2015 (“Effective Date”) between The Board Of Trustees Of The University Of Illinois, a body corporate and politic of the State of Illinois, 352 Henry Administration Building, 506 S. Wright St., Urbana, Illinois 61801 (“University”) and Apotheca Therapeutics a Delaware corporation, with a principal place of business at 1401 Foch Street, Fort Worth, TX 76107 (“Licensee” or “Company”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 4th, 2024 • Actuate Therapeutics, Inc. • Services-commercial physical & biological research • Texas
This EMPLOYMENT AGREEMENT (this "Agreement"), is entered into to be effective as of April 15, 2015 (the "Effective Date"), by and between Apotheca Therapeutics, Inc. a Delaware corporation (the "Company"), and Daniel Schmitt, an individual currently residing at [***] (the "Executive").
Re: Consulting Agreement Dear Mr. Lytle:Consulting Agreement • March 4th, 2024 • Actuate Therapeutics, Inc. • Services-commercial physical & biological research • Delaware
You and Actuate Therapeutics, Inc. (the “Company”) have had discussions concerning your desire to render professional consulting services to the Company as described herein. The Company wants to engage your services, and you want to render them, subject to the terms and conditions of this letter agreement (this “Agreement”), which shall become effective upon the last date of signature of this Agreement by both parties (the “Effective Date”). For the purpose of this Agreement, you shall be referred to herein as “Consultant.”
ContractEmployment Agreement • March 4th, 2024 • Actuate Therapeutics, Inc. • Services-commercial physical & biological research • Texas
This EMPLOYMENT AGREEMENT (this “Agreement”), is entered into to be effective as of June 1, 2022 (the “Effective Date”), by and between Actuate Therapeutics, Inc., a Delaware corporation (the “Company”), and Andrew Mazar, an individual currently residing at 598 Rockefeller Road, Lake Forest IL 60045 (the “Executive”).
ACTUATE THERAPEUTICS INC. FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • March 4th, 2024 • Actuate Therapeutics, Inc. • Services-commercial physical & biological research • Delaware
THIS FOURTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”), is made as of the 30th day of November, 2022, by and among ACTUATE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Subsection 6.9 hereof.
LICENSE AGREEMENTLicense Agreement • March 4th, 2024 • Actuate Therapeutics, Inc. • Services-commercial physical & biological research • Illinois
This License Agreement (“Agreement”) made this 31st day of March, 2015 (the "Effective Date") by and between Northwestern University, an Illinois corporation having a principal office at 633 Clark Street, Evanston, Illinois 60208 (hereinafter referred to as "Northwestern") and Apotheca Therapeutics, Inc., a Delaware corporation having a principal office at 1401 Foch Street, Fort Worth, TX 76107 (hereinafter referred to as "Licensee") (each of Northwestern and Licensee individually a "Party" and collectively the "Parties").
